BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer

Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Cancer (Impact Factor: 4.9). 05/2009; 115(10):2222-33. DOI: 10.1002/cncr.24200
Source: PubMed

ABSTRACT In women at increased risk for breast and ovarian cancer, the identification of a mutation in breast cancer gene 1 (BRCA1) and BRCA2 has important implications for screening and prevention counseling. Uncertainty regarding the role of BRCA1 and BRCA2 testing in high-risk women from diverse ancestral backgrounds exists because of variability in prevalence estimates of deleterious (disease-associated) mutations in non-white populations. In this study, the authors examined the prevalence of BRCA1 and BRCA2 mutations in an ethnically diverse group of women who were referred for genetic testing.
In this cross-sectional analysis, the prevalence of BRCA1 and BRCA2 mutations was assessed in a group of non-Ashkenazi Jewish women who underwent genetic testing.
From 1996 to 2006, 46,276 women who met study criteria underwent DNA full-sequence analysis of the BRCA1 and BRCA2 genes. Deleterious mutations were identified in 12.5% of women, and recurrent deleterious mutations (prevalence >2%) were identified in all ancestral groups. Women of non-European descent were younger (mean age, 45.9 years; standard deviation [SD], 11.6 years) than European women (mean age, 50 years; SD, 11.9 years; P < .001). Women of African (15.6%; odds ratio [OR], 1.3 [95% confidence interval (95% CI), 1.1-1.5]) and Latin American (14.8%; OR, 1.2 [95% CI, 1.1-1.4]) ancestries had a significantly higher prevalence of deleterious BRCA1 and BRCA2 mutations compared with women of Western European ancestry (12.1%), primarily because of an increased prevalence of BRCA1 mutations in those 2 groups. Non-European ethnicity was associated strongly with having a variant of uncertain significance; however, reclassification decreased variant reporting (from 12.8%-->5.9%), and women of African ancestry experienced the largest decline (58%).
Mutation prevalence was found to be high among women who were referred for clinical BRCA1 and BRCA2 testing, and the risk was similar across diverse ethnicities. BRCA1 and BRCA2 testing is integral to cancer risk assessment in all high-risk women.

Download full-text


Available from: Dmitry Pruss, Oct 28, 2014
  • Source
    • "found to carry a BRCA1 variant of uncertain significance (VUS). These variants were classified as uncertain because they occurred in families wherein segregation analysis had not been done or in whom the segregation analysis was not informative and thus the VUS had unknown effects on breast and ovarian cancer risk [Hall et al., 2009; Spearman et al., 2008; Sweet et al., 2009]. As whole genome and exome sequencing becomes a more prevalent practice, more VUSs in BRCA1 will be uncovered, and increasingly women will face the quandary of an uninformative genetic test. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Missense substitutions of uncertain clinical significance in the BRCA1 gene are a vexing problem in genetic counseling for women who have a family history of breast cancer. In this study, we evaluated the functions of 29 missense substitutions of BRCA1 in two DNA repair pathways. Repair of double strand breaks by homology directed recombination (HDR) had been previously analyzed for 16 of these BRCA1 variants, and 13 more variants were analyzed in this study. All 29 variants were also analyzed for function in double strand break repair by the single strand annealing (SSA) pathway. We found that among the pathogenic mutations in BRCA1, all were defective for DNA repair by either pathway. The HDR assay was accurate since all pathogenic mutants were defective for HDR, and all non-pathogenic variants were fully functional for HDR. Repair by SSA accurately identified pathogenic mutants, but several non-pathogenic variants were scored as defective or partially defective. These results indicated that specific amino acid residues of the BRCA1 protein have different effects in the two related DNA repair pathways, and these results validate the HDR assay as highly correlative with BRCA1-associated breast cancer.
    Human Mutation 03/2013; 34(3). DOI:10.1002/humu.22251 · 5.05 Impact Factor
  • Source
    • "In the general population, 5%–10% of all breast cancers are due to mutations in the BRCA1 or BRCA2 genes; these genetic mutations are also associated with a high incidence of premenopausal, early onset breast cancer (Chen et al., 2002). BRCA1/2 mutations may explain some of the increased incidence of early onset breast cancer in AAW, especially those from high-risk families (Dangel et al., 1999; Gao, Neuhausen, Cummings, Luce, & Olopade, 1997; Gao et al., 2000; Hall et al., 2009). AAW also experience a high rate of mutations (gene variants) of uncertain significance, which makes risk assessment and genetic test result interpretation quite complex (Nanda et al., 2005; Opatt, Morrow, & Daly, 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined healthcare providers' perceptions of genetic counseling and testing in African American women at moderate to high-risk of carrying a BRCA1/2 mutation. We conducted 20 in-depth interviews with genetic counselors (n = 5), medical oncologists (n = 8), obstetrician/gynecologists (n = 2) and surgeons (n = 5). Interviews were audiotaped, transcribed and independently coded by two individuals using a content analysis approach. Seven themes emerged relevant to providers' perceptions of African American women's use of BRCA1/2 genetic services: access factors, cultural beliefs and preferences, effects of testing, patient motivators for genetic counseling and testing, patient-provider communication, reasons for provider referral, and reasons for patient refusal. Providers identified individual- and system-level barriers to African American women's use of genetic services, including lack of follow-up after referrals to genetic specialists and challenges to obtaining financial coverage for under- and uninsured high-risk women. Results have implications for physician and patient education regarding appropriate referrals to and uptake of genetic services in at-risk African American women.
    Journal of Genetic Counseling 08/2011; 20(6):674-89. DOI:10.1007/s10897-011-9396-3 · 1.75 Impact Factor
  • Source
    • "(Struewing et al. 1997; Fodor et al. 1998). Among the families with multiple breast and ovarian cancers from Western and Central Europe, this mutation is respectively two and four times as common as 185delAG (Hall et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of our study was to establish the frequency and distribution of the four most common BRCA1 mutations in Polish general population and in a series of breast cancer patients. Analysis of the population frequency of 5382insC (c.5266dupC), 300T >G (p.181T >G), 185delAG (c.68_69delAG) and 3819del5 (c.3700_3704del5) mutations of the BRCA1 gene were performed on a group of respectively 16,849, 13,462, 12,485 and 3923 anonymous samples collected at birth in seven Polish provinces. The patient group consisted of 1845 consecutive female breast cancer cases. The most frequent BRCA1 mutation in the general population was 5382insC found in 29 out of 16,849 samples (0.17%). 300T >G and 3819del5 mutations were found in respectively 11 of 13,462 (0.08%) and four of 3923 (0.1%) samples. The population prevalence for combined Polish founder 5382insC and 300T >G mutations was 0.25% (1/400). The frequencies of 5382insC and 300T >G carriers among consecutive breast cancer cases were, respectively, 1.9% (35/1845) and 1.2% (18/1486). Comparing these data with the population frequency, we calculated the relative risk of breast cancer for 5382insC mutation at OR = 17 and for 300T >G mutation at OR = 26. Our results, based on large population studies, show high frequencies of founder 5382insC and 300T >G BRCA1 mutations in Polish general population. Carriage of one of these mutations is connected with a very high relative risk of breast cancer.
    Journal of applied genetics 04/2011; 52(3):325-30. DOI:10.1007/s13353-011-0040-6 · 1.90 Impact Factor
Show more